| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 16,101 | 15,054 |
| Increase (decrease) in cash, cash equivalents and restricted cash | -19,434 | -8,273 |
| Cash and cash equivalents at beginning of period | 25,176 | - |
| Cash and cash equivalents at end of period | 5,742 | - |
Atara Biotherapeutics, Inc. (ATRA)
Atara Biotherapeutics, Inc. (ATRA)